Effective November 16, 2026, the U.S. Food and Drug Administration (FDA) formally initiated an agency-wide transition replacing the terms ‘Artificial Intelligence’ and ‘AI’ with ‘Super Intelligence’ and ‘SI’ across newly issued public-facing documents, digital communications, and web portals. The administrative nomenclature shift implements White House Executive Order 14434, signed on September 29, 2026, but the agency confirmed that the update is strictly terminological and does not alter underlying regulatory requirements, review standards, or submission pathways for medical product sponsors and academic clinical trial investigators.
What happened
On November 16, 2026, the FDA began operational implementation of Executive Order 14434, titled ‘Inaugurating the Era of Super Intelligence.’ Under the directive, executive departments and regulatory agencies must, to the maximum extent permitted by law, substitute ‘Super Intelligence’ (SI) for ‘Artificial Intelligence’ (AI) in official correspondence, press announcements, public reports, and digital guidance hubs.
The transition began across the agency’s primary digital health assets, notably within the Center for Devices and Radiological Health (CDRH), the Center for Drug Evaluation and Research (CDER), and the Center for Biologics Evaluation and Research (CBER). Web resources cataloging digital health and machine learning initiatives—including public directories of cleared algorithmic software—began adopting the updated nomenclature.
Crucially, the FDA issued accompanying stakeholder guidance emphasizing that the terminology change is an administrative alignment rather than a substantive alteration of medical product law. Agency officials clarified that the shift imposes no new evidentiary burdens on device developers, pharmaceutical sponsors, or academic research institutions conducting clinical trials.
Key details and scope of the transition
The legal scope of the transition is anchored directly to the statutory definition of artificial intelligence established under federal law. Executive Order 14434 specifies that ‘Super Intelligence’ and ‘SI’ encompass the definition set forth in 15 U.S.C. 9401(3)—the provision enacted by the National Artificial Intelligence Initiative Act of 2020.
Consequently, the shift establishes no higher capability threshold and requires no demonstration of theoretical superintelligence before falling under agency oversight. Any machine-based system meeting the statutory criteria under Section 9401(3) is now referred to administratively as Super Intelligence in newly generated communications.
To provide regulatory clarity, the FDA outlined key operational parameters governing the transition:
- Prospective application: The new terminology applies to newly published public communications, guidance documents, agency web pages, and formal statements issued on or after November 16, 2026.
- Preservation of legacy guidance: Existing guidance documents, formal notices, and established frameworks—such as Good Machine Learning Practice (GMLP) guiding principles and Predetermined Change Control Plan (PCCP) frameworks—remain fully in effect under their original text.
- No mandatory external rebranding: Medical device manufacturers, biotechnology sponsors, and academic investigators are not required to rename commercial products, revise proprietary software code, or re-label cleared devices.
- Unchanged submission processing: Electronic submission gateways, standardized templates, and formal premarket filings continue operating without administrative delays or rejection based on terminology choices.
The table below summarizes operational impact across key agency functions and regulatory interfaces:
| Regulatory Area | Prior FDA Terminology | Updated FDA Terminology | Operational and Legal Impact |
|---|---|---|---|
| Public Communications | Artificial Intelligence (AI) | Super Intelligence (SI) | Rebranded across newly issued web content, press releases, and speeches |
| Statutory Authority | 15 U.S.C. 9401(3) | 15 U.S.C. 9401(3) | Substantive legal definition unchanged; SI covers existing statutory scope |
| Regulatory Filings | AI/ML-Enabled Software | SI/ML-Enabled Software | Dual terminology accepted; zero changes to clinical evidence thresholds |
| Premarket Review | 510(k), De Novo, PMA | 510(k), De Novo, PMA | Substantial equivalence, safety, and effectiveness standards unchanged |
| Product Labeling | AI-specified indications | Sponsor discretion | No mandatory labeling recalls or rebranding required for marketed products |
Background and context
President Donald J. Trump signed Executive Order 14434 on September 29, 2026, with publication in the Federal Register on October 2, 2026 (91 FR 63129). The order directed executive agencies to align non-statutory documentation within 45 days, culminating in the November 16 implementation date. The action reflects a wider realignment across the federal AI regulatory landscape, which continues to evolve through competing federal priorities and state enactments.
Within the Department of Health and Human Services (HHS), sister agencies are executing parallel updates. The National Institutes of Health (NIH) adjusted public research portals to reflect current NIH AI policies while preserving existing grant administration frameworks and peer-review confidentiality rules. Earlier in autumn 2026, the Department of Justice launched an interagency task force examining algorithmic security under the same executive nomenclature.
Administrative law creates clear boundaries regarding statutory terminology. Because statutes passed by Congress explicitly codify ‘artificial intelligence,’ agencies cannot unilaterally alter underlying legislative phrasing. Consequently, citations in formal legal pleadings, Federal Food, Drug, and Cosmetic Act (FD&C Act) provisions, and congressional reports will continue citing the enacted statutory language until Congress acts.
Reaction from legal and regulatory analysts
Regulatory attorneys, life sciences trade organizations, and academic policy analysts responded to the FDA’s announcement with pragmatic guidance for product sponsors.
In a legal alert, regulatory counsel at Arnold and Porter emphasized that life sciences companies must distinguish rhetorical rebranding from legal compliance. Counsel stressed that FDA review divisions—including CDRH’s Digital Health Center of Excellence—continue evaluating medical algorithms on technical validity, risk management, cybersecurity, and clinical performance rather than semantic descriptors.
Attorneys at Wiley Rein LLP noted that Executive Order 14434 applies internally to executive branch agencies rather than creating binding mandates on private industry. The firm advised corporate compliance teams and university research offices that existing contracts, clinical trial agreements, and regulatory dossiers do not require retrospective revisions simply to replace legacy terminology.
Medical device industry representatives welcomed the FDA’s clear statement that electronic submission gateways (such as eSTAR) and premarket review schedules will proceed without disruption, avoiding administrative backlogs in premarket clearance cycles for computational diagnostics and digital therapeutics.
What it means for researchers, universities and research offices
For academic research institutions, university technology transfer offices, and principal investigators, the FDA’s adoption of Super Intelligence terminology requires practical awareness without operational disruption:
- Clinical trial design and IRB review: Academic medical centers conducting investigator-initiated clinical trials involving software algorithms do not need to revise existing protocols, consent forms, or institutional review board (IRB) filings solely to adjust nomenclature. IRBs and clinical investigators should maintain focus on substantive ethical safeguards, data integrity, patient protection, and AI output verification rather than cosmetic terminology shifts.
- Regulatory submissions and translational spin-offs: University researchers preparing translational technologies for FDA commercialization pathways—such as De Novo classification requests or 510(k) notifications—may submit documentation using standard academic terminology (AI/ML) or the new agency phrasing (SI). Review divisions will evaluate both terms interchangeably. No filing will be rejected or placed on hold due to nomenclature preference.
- Sponsored research and contracting: University sponsored research offices and tech transfer teams do not need to amend active industry research agreements, software licenses, or material transfer agreements. Existing intellectual property definitions covering algorithmic inventions remain legally binding and fully enforceable.
- Federal grant reporting and agency correspondence: Investigators communicating with FDA project officers, Q-Submission (Pre-Sub) program liaisons, or NIH grant administrators may observe agency staff using ‘Super Intelligence’ in formal responses. Researchers may adopt the terminology in official agency correspondence if desired, but grant compliance standards and technical deliverables remain anchored to original funding opportunity specifications.
What happens next
The November 16, 2026 rollout marks the beginning of an incremental implementation schedule across the FDA’s operational units:
- Phased digital maintenance: Agency web developers and communications teams will progressively update remaining online guidance indices, educational webinars, and public directories during scheduled IT maintenance cycles through early 2027.
- Draft guidance releases: Forthcoming draft guidance documents anticipated in early 2027—including expected updates on life-cycle management for adaptive clinical algorithms—will formally incorporate Super Intelligence terminology in their narrative preambles while maintaining technical continuity with international harmonized standards.
- OSTP legislative language: In accordance with Executive Order 14434, the White House Office of Science and Technology Policy (OSTP) is expected to draft proposed statutory amendments for submission to Congress, seeking to harmonize definitions across Title 15 and Title 21 of the United States Code.
- International harmonization: The FDA reiterated its commitment to continue collaborating with international regulatory partners—including the International Medical Device Regulators Forum (IMDRF) and the World Health Organization (WHO)—ensuring that domestic terminology changes do not disrupt multilateral consensus on machine learning safety and algorithmic validation.
Sources
- U.S. Food and Drug Administration (FDA), Super Intelligence Terminology Transition Notice Under Executive Order 14434, published 2026-11-16.
- Federal Register, Executive Order 14434: Inaugurating the Era of Super Intelligence (91 FR 63129), published 2026-10-02.
- Arnold and Porter, Federal Agencies Begin Terminology Transition Under Executive Order 14434: What Life Sciences Sponsors Need to Know, published 2026-10-14.
- Wiley Rein LLP, Administration Replaces ‘AI’ with ‘Super Intelligence’ Across Federal Agencies: Practical Compliance Implications, published 2026-10-16.
- Regulations.ai, Executive Order 14434 Implementation Tracker: FDA and HHS Transitions, published 2026-11-16.







